SlideShare uma empresa Scribd logo
1 de 79
The Academic Center and Development of Future Treatments for Malignant Gliomas ,[object Object],[object Object],[object Object]
Malignant Gliomas ,[object Object],[object Object],[object Object],[object Object],[object Object]
Typical Treatment Course for Gliomas 1.  Surgery-biopsy or resection 2.  Radiation with low dose temozolomide (TMZ) 3.  High dose or metronomic TMZ alone 4.  F/u with MRI scans every two months 5.  If MRI documented progression: Avastin, repeat resection, radiosurgery, or clinical trials
 
 
 
Preop Axial T1  with Contrast
Pre-resection motor stimulation with Ojemann Stimulator
Post Resection:  Motor Stimulation
Gliadel Wafers Placed
Glioblastoma:  post-mortem
Goal of Talk ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Glioma Research Group ,[object Object],[object Object],[object Object],[object Object],[object Object]
Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response Vascularized Periphery Perinecrotic Rim (Pseudopalisades ) Necrotic Area Thrombotic Vessel
Targeting the Perinecrotic Rim in Glioblastoma Multiforme via  Modulation of the Endoplasmic Reticulum Stress Response
Concept of ER stress ,[object Object],[object Object],[object Object]
[object Object]
Targeting the Perinecrotic Rim in Glioblastoma Multiforme via  Modulation of the Endoplasmic Reticulum Stress Response
•
HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress
GRP78 LEVELS IN GLIOBLASTOMA TISSUE SECTIONS
TMZ increases GRP78 in glioblastoma cell lines. GRP78 Actin GRP78 Actin
U87 glioblastoma cells transfected with different concentrations of GRP78 siRNA  and GFP siRNA fused to rhodamine.
 
 
 
Glioma Cancer Stem Cells and ER Stress
Neural Stem Cells and the  Origin of Gliomas Nader Sanai, M.D., Arturo Alvarez-Buylla, Ph.D., and Mitchel S. Berger, M.D.
Glioma Cancer Stem Cells (GCSC) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
x16 x48 Morphology of GCSC (D431)
TMZ treatment with 15% BSA Treatment in 6well plate and transfer to 96well plate for MTT analysis  2009-10-01 TMZ (uM) % O.D. at 490nm TMZ (uM) % O.D. at 490nm Conclusion: TMZ is not cytotoxic to CSC.  U251 w/ 15% BSA CSC w/ 15% BSA 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80 90 100 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80
Is DMC Cytotoxic To Glioma Cancer Stem Cells (GCSC) ?  U87 U251 CSC (single) CSC (sphere) DMC (uM) % O.D. at 490nm Condition: Medium +10% BSA, 48hr treatment 0 20 40 60 80 100 120 140 0 10 20 30 40 50 60 70 80 90 100
Does DMC Enduces ER Stress in Glioma Cancer Stem Cells (CSC) ?  1  2  3  4  5  GRP78 Chop Actin 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM
Does DMC Induce ER Stress in Glioma Cancer Stem Cells (CSC) ?  1  2  3  4  5  GRP78 Chop Actin Parp MGMT Conclusion: ER stress upregulated at DMC 60 uM in CSC.  DMC at 60 uM reduces MGMT levels. 24hr treatment Cl. parp Parp 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM CSC-D431
 
 
Perillyl Alcohol (POH) ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
May/2006 Dec/2006 Fibrillary Astrocytoma grade II ______________________________________________________________________________________________________________________________________   May/2008 Jun/2007
JAN / 2007 MAY / 2008 Recurrente Anaplastic Oligodendroglioma ______________________________________________________________________________________________________________________________________ NOV / 2008
Disease-free survival (6 months) ______________________________________________________________________________________________________________________________________ The median PFS rate was 48.2% for patients with GBM, 60% for patients with AA, and 66.6% for patients with AO.
USA DEVELOPMENT ,[object Object],[object Object],[object Object]
 
 
Development of an Implantable Pump for Convection Enhanced Delivery
What’s currently available for drug delivery for brain tumors ,[object Object],[object Object],[object Object],[object Object],www.pharmaco-kinesis.com
CONVECTION ENHANCED DELIVERY ,[object Object],[object Object],[object Object]
 
www.pharmaco-kinesis.com Convection Enhanced Trials 1.  Some success in Phase I/II trials  2.  No clear success in Phase III trials  (Neopharm, Transmid) 3.  Question:  Lack of success from delivery or from drug?
[object Object]
[object Object]
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],www.pharmaco-kinesis.com
9/19/2008 Property of Pharmaco Kinesis Corp.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],9/19/2008 Property of Pharmaco Kinesis Corp. www.pharmaco-kinesis.com
Fig. 8 www.pharmaco-kinesis.com Medication Storage and Delivery System Circulation pump Medication pump Medication Reservoirs Catheter Catheter Cross Section Fluid Circulation System
 
www.pharmaco-kinesis.com
www.pharmaco-kinesis.com
Fig. 3B www.pharmaco-kinesis.com
[object Object],[object Object],[object Object],9/19/2008 Property of Pharmaco-Kinesis Corp. www.pharmaco-kinesis.com
Cir. And Reservoir Pump ( Bartels ) Active Valve ( Bartels ) Flow Sensor ( Sensirion ) Pressure Sensor Temperature Sensor ( GE ) pH Sensor ( WPI ) Reservior  ( Metal Bellows ) www.pharmaco-kinesis.com
www.pharmaco-kinesis.com Wireless Radio High level goals High level tasks Internal states Growth signal Intracranial pressure Tissue condition Tissue metabolism Table of parameters Circulate Inject 1 Inject 2 Inject 3 Pump Pump-valve Pump-valve Pump-valve VEGF Spectrometer Pressure sensor pH sensor Oxygen sensor Solid Tumor Microcontroller Medication Tumor Fluid
What type of drugs to place? ,[object Object],[object Object],[object Object],[object Object],www.pharmaco-kinesis.com
www.pharmaco-kinesis.com Avastin in 28-day pump Implantated IP CPT-11 D7 – D11 D14 – D118 D21 – D25 D28 – D32 1 st  dose of Avastin  2nd dose of Avastin
VIDEO OF IMPLANTABLE PUMP ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
RCR vectors for  intracellular chemotherapy   ,[object Object], gag pol env U5 R CMV U5 R U3 IRES CD 5-fluorocytosine (non-toxic)  5-fluorouracil (toxic)
U87 intra-cerebral glioma model for  in vivo  analysis of RCR vector-mediated suicide gene therapy Establishment  of tumor  1 x 10  t.u. ACE-CD injected into tumor  4 Intraperitoneal injection  of 5-FC  H&E / IHC Survival analysis virus spread 2 x 10  U87 tumor cells injected into nude mice  5
RCR-CD + 5-FC achieves significantly prolonged survival in an intracranial glioma model ,[object Object],[object Object],▪  Eventual death of treated animals due to metastatic spread of glioma cells to ectopic intracranial sites (cerebellum, brainstem) median survival: ≈  65 days
RCR-mediated suicide gene therapy achieves significant inhibition of primary intracranial tumor growth ,[object Object],[object Object],[object Object]
U01:  Pre-clinical Development of RCR  ,[object Object],[object Object]
Phase I/II Clinical Trial ,[object Object],[object Object],[object Object],[object Object]
Immunotherapy ,[object Object],[object Object],[object Object]
Immunotherapy ,[object Object],[object Object],[object Object],[object Object]
CONCLUSION ,[object Object],[object Object],[object Object],[object Object]
Future Development ,[object Object],[object Object],[object Object],[object Object]
CONCLUSION ,[object Object],[object Object],[object Object],www.pharmaco-kinesis.com

Mais conteúdo relacionado

Mais procurados

Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyMohamed Abdulla
 
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Fundación Ramón Areces
 
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Clinical Surgery Research Communications
 
Chemotherapy for brain tumours
Chemotherapy for brain tumoursChemotherapy for brain tumours
Chemotherapy for brain tumoursvisheshrohatgi
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbituxeman youssif
 
Panitumumab (vectibix)
Panitumumab (vectibix)Panitumumab (vectibix)
Panitumumab (vectibix)Vibhay Pareek
 
Tu Esmo Imaging Of Glioma Ppt
Tu Esmo Imaging Of Glioma PptTu Esmo Imaging Of Glioma Ppt
Tu Esmo Imaging Of Glioma Pptfondas vakalis
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenEurasian Federation of Oncology
 
Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Patwant Dhillon
 
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
 
Enabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsEnabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsDiscoverX Corporation
 
Optimizing Chemotherapy For Malignant Glioma
Optimizing Chemotherapy For Malignant GliomaOptimizing Chemotherapy For Malignant Glioma
Optimizing Chemotherapy For Malignant Gliomafondas vakalis
 
LUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABLUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABHeena Parveen
 
The immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyThe immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyPaul D. Rennert
 
Identify Compounds that Rescue Disease Relevant Mutant Membrane Proteins
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsIdentify Compounds that Rescue Disease Relevant Mutant Membrane Proteins
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
 
Inmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliadaInmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliadaAlberto IC
 
EGFR -TkI resistance pathways
EGFR -TkI resistance pathways  EGFR -TkI resistance pathways
EGFR -TkI resistance pathways Maria Jubran
 
Targeted therapy in breast cancer
Targeted therapy in breast cancerTargeted therapy in breast cancer
Targeted therapy in breast cancerdr-kannan
 

Mais procurados (20)

Introduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in OncologyIntroduction to Targeted Therapies in Oncology
Introduction to Targeted Therapies in Oncology
 
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''
 
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
Lnc rna neat1 is involved in temozolomide resistance by regulating mgmt in gl...
 
Chemotherapy for brain tumours
Chemotherapy for brain tumoursChemotherapy for brain tumours
Chemotherapy for brain tumours
 
Clinical studies erbitux
Clinical studies  erbituxClinical studies  erbitux
Clinical studies erbitux
 
Panitumumab (vectibix)
Panitumumab (vectibix)Panitumumab (vectibix)
Panitumumab (vectibix)
 
Tu Esmo Imaging Of Glioma Ppt
Tu Esmo Imaging Of Glioma PptTu Esmo Imaging Of Glioma Ppt
Tu Esmo Imaging Of Glioma Ppt
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
 
Erbitux
ErbituxErbitux
Erbitux
 
Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”Pembrolizumab - “Treatment of melanoma has never been this promising”
Pembrolizumab - “Treatment of melanoma has never been this promising”
 
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)
 
Enabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to CombinationsEnabling Cancer Immunotherapy: From Discovery to Combinations
Enabling Cancer Immunotherapy: From Discovery to Combinations
 
Optimizing Chemotherapy For Malignant Glioma
Optimizing Chemotherapy For Malignant GliomaOptimizing Chemotherapy For Malignant Glioma
Optimizing Chemotherapy For Malignant Glioma
 
LUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMABLUNG CANCER TREATMENT BY NIVOLUMAB
LUNG CANCER TREATMENT BY NIVOLUMAB
 
The immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapyThe immune checkpoint landscape in 2015: combination therapy
The immune checkpoint landscape in 2015: combination therapy
 
Identify Compounds that Rescue Disease Relevant Mutant Membrane Proteins
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsIdentify Compounds that Rescue Disease Relevant Mutant Membrane Proteins
Identify Compounds that Rescue Disease Relevant Mutant Membrane Proteins
 
Inmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliadaInmunoterapia y cancer version ampliada
Inmunoterapia y cancer version ampliada
 
EGFR -TkI resistance pathways
EGFR -TkI resistance pathways  EGFR -TkI resistance pathways
EGFR -TkI resistance pathways
 
Targeted therapy in breast cancer
Targeted therapy in breast cancerTargeted therapy in breast cancer
Targeted therapy in breast cancer
 
erbitux
erbituxerbitux
erbitux
 

Destaque

Rudy De Nolf - Het Kancentrum in Brugge
Rudy De Nolf - Het Kancentrum in BruggeRudy De Nolf - Het Kancentrum in Brugge
Rudy De Nolf - Het Kancentrum in BruggeETWIE
 
Evaluation of Cloud-based Personal Health Records
Evaluation of Cloud-based Personal Health RecordsEvaluation of Cloud-based Personal Health Records
Evaluation of Cloud-based Personal Health RecordsAbdussalam Alawini
 
Metadata is een netwerk v4
Metadata is een netwerk v4Metadata is een netwerk v4
Metadata is een netwerk v4Bibnet vzw
 
1/31旅遊規劃
1/31旅遊規劃1/31旅遊規劃
1/31旅遊規劃besttseb
 
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016Optimization conference
 
HxR 2015: "Our Calling: Improve Health"
HxR 2015: "Our Calling: Improve Health"HxR 2015: "Our Calling: Improve Health"
HxR 2015: "Our Calling: Improve Health"Amy Cueva
 
Патент на полезную модель Республики Беларусь
Патент на полезную модель Республики БеларусьПатент на полезную модель Республики Беларусь
Патент на полезную модель Республики БеларусьИван Иванов
 
Indonesia 2013 oleh Firmanzah
Indonesia 2013 oleh FirmanzahIndonesia 2013 oleh Firmanzah
Indonesia 2013 oleh Firmanzahppibelanda
 
10 conseils pour recruter un collaborateur efficace pour son auto école !
10 conseils pour recruter un collaborateur efficace pour son auto école !10 conseils pour recruter un collaborateur efficace pour son auto école !
10 conseils pour recruter un collaborateur efficace pour son auto école !bpermis
 
Get paid to holiday
Get paid to holidayGet paid to holiday
Get paid to holidayTara Dean
 
Managing Value-Added Services...
Managing Value-Added Services...Managing Value-Added Services...
Managing Value-Added Services...jpotter49505
 
4 Seasons Virtual Field Trip. Fricke
4 Seasons Virtual Field Trip. Fricke4 Seasons Virtual Field Trip. Fricke
4 Seasons Virtual Field Trip. Frickehhfricke
 
LS 607 Managing Organizational Change chapter 5
LS 607 Managing Organizational Change chapter 5LS 607 Managing Organizational Change chapter 5
LS 607 Managing Organizational Change chapter 5BHUOnlineDepartment
 

Destaque (17)

Rudy De Nolf - Het Kancentrum in Brugge
Rudy De Nolf - Het Kancentrum in BruggeRudy De Nolf - Het Kancentrum in Brugge
Rudy De Nolf - Het Kancentrum in Brugge
 
Evaluation of Cloud-based Personal Health Records
Evaluation of Cloud-based Personal Health RecordsEvaluation of Cloud-based Personal Health Records
Evaluation of Cloud-based Personal Health Records
 
Metadata is een netwerk v4
Metadata is een netwerk v4Metadata is een netwerk v4
Metadata is een netwerk v4
 
1/31旅遊規劃
1/31旅遊規劃1/31旅遊規劃
1/31旅遊規劃
 
Croquis 2.9 caminos 1
Croquis 2.9 caminos 1Croquis 2.9 caminos 1
Croquis 2.9 caminos 1
 
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016
Марина Чернова, Промо-страницы для WOW-товаров, Optimization 2016
 
HxR 2015: "Our Calling: Improve Health"
HxR 2015: "Our Calling: Improve Health"HxR 2015: "Our Calling: Improve Health"
HxR 2015: "Our Calling: Improve Health"
 
Патент на полезную модель Республики Беларусь
Патент на полезную модель Республики БеларусьПатент на полезную модель Республики Беларусь
Патент на полезную модель Республики Беларусь
 
Indonesia 2013 oleh Firmanzah
Indonesia 2013 oleh FirmanzahIndonesia 2013 oleh Firmanzah
Indonesia 2013 oleh Firmanzah
 
10 conseils pour recruter un collaborateur efficace pour son auto école !
10 conseils pour recruter un collaborateur efficace pour son auto école !10 conseils pour recruter un collaborateur efficace pour son auto école !
10 conseils pour recruter un collaborateur efficace pour son auto école !
 
Get paid to holiday
Get paid to holidayGet paid to holiday
Get paid to holiday
 
Managing Value-Added Services...
Managing Value-Added Services...Managing Value-Added Services...
Managing Value-Added Services...
 
Presentation fmm food hygiene
Presentation fmm food hygienePresentation fmm food hygiene
Presentation fmm food hygiene
 
4 Seasons Virtual Field Trip. Fricke
4 Seasons Virtual Field Trip. Fricke4 Seasons Virtual Field Trip. Fricke
4 Seasons Virtual Field Trip. Fricke
 
Presentation1
Presentation1Presentation1
Presentation1
 
LS 607 Managing Organizational Change chapter 5
LS 607 Managing Organizational Change chapter 5LS 607 Managing Organizational Change chapter 5
LS 607 Managing Organizational Change chapter 5
 
Singapore
SingaporeSingapore
Singapore
 

Semelhante a Dr. Thomas Chen, UCI grand rounds 7-28-2010

High grade glioma, standard of care & new advances..
High grade glioma, standard of care & new advances.. High grade glioma, standard of care & new advances..
High grade glioma, standard of care & new advances.. Osama Elzaafarany, MD.
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Cytokinine
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)Vinblast
 
Update in Breast Imaging Radiopharmaceuticals
Update in Breast Imaging RadiopharmaceuticalsUpdate in Breast Imaging Radiopharmaceuticals
Update in Breast Imaging Radiopharmaceuticals@Saudi_nmc
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6ScottJordan
 
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. Salem
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. SalemChemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. Salem
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. SalemProf. Mohamed Labib Salem
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDMelanoma Research Foundation
 
SciTech Development Company Presentation
SciTech Development Company PresentationSciTech Development Company Presentation
SciTech Development Company PresentationSciTech Development
 
Sk microfluidics and lab on-a-chip-ch6
Sk microfluidics and lab on-a-chip-ch6Sk microfluidics and lab on-a-chip-ch6
Sk microfluidics and lab on-a-chip-ch6stanislas547
 
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug CompoundST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug CompoundSciTech Development
 
Presentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumorsPresentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumorsProfessor Yasser Metwally
 
brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptxssuserf649e6
 
Lab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringLab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringstanislas547
 
Radiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsRadiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsDhiman Das
 
Clinical Trials in BNCT at the MIT Research Reactor
Clinical Trials in BNCT at the MIT Research ReactorClinical Trials in BNCT at the MIT Research Reactor
Clinical Trials in BNCT at the MIT Research Reactorkent.riley
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3ScottJordan
 

Semelhante a Dr. Thomas Chen, UCI grand rounds 7-28-2010 (20)

High grade glioma, standard of care & new advances..
High grade glioma, standard of care & new advances.. High grade glioma, standard of care & new advances..
High grade glioma, standard of care & new advances..
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)
 
Systemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic DiseaseSystemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic Disease
 
Update in Breast Imaging Radiopharmaceuticals
Update in Breast Imaging RadiopharmaceuticalsUpdate in Breast Imaging Radiopharmaceuticals
Update in Breast Imaging Radiopharmaceuticals
 
Intra Tumoral Drug Delivery
Intra Tumoral Drug DeliveryIntra Tumoral Drug Delivery
Intra Tumoral Drug Delivery
 
Vital Signs Edition #6
Vital Signs   Edition #6Vital Signs   Edition #6
Vital Signs Edition #6
 
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. Salem
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. SalemChemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. Salem
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. Salem
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
 
SciTech Development Company Presentation
SciTech Development Company PresentationSciTech Development Company Presentation
SciTech Development Company Presentation
 
Sk microfluidics and lab on-a-chip-ch6
Sk microfluidics and lab on-a-chip-ch6Sk microfluidics and lab on-a-chip-ch6
Sk microfluidics and lab on-a-chip-ch6
 
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug CompoundST-001 NanoFenretinide - SciTech Development Lead Drug Compound
ST-001 NanoFenretinide - SciTech Development Lead Drug Compound
 
Presentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumorsPresentation...Non-surgical management of brain tumors
Presentation...Non-surgical management of brain tumors
 
brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptx
 
Lab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoringLab-on-a-Chip for cancer diagnostics and monitoring
Lab-on-a-Chip for cancer diagnostics and monitoring
 
Immunotherapy for cancer
Immunotherapy for cancer Immunotherapy for cancer
Immunotherapy for cancer
 
Radiosenitizers and radioprotectors
Radiosenitizers and radioprotectorsRadiosenitizers and radioprotectors
Radiosenitizers and radioprotectors
 
Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 
Clinical Trials in BNCT at the MIT Research Reactor
Clinical Trials in BNCT at the MIT Research ReactorClinical Trials in BNCT at the MIT Research Reactor
Clinical Trials in BNCT at the MIT Research Reactor
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
 

Dr. Thomas Chen, UCI grand rounds 7-28-2010

  • 1.
  • 2.
  • 3. Typical Treatment Course for Gliomas 1. Surgery-biopsy or resection 2. Radiation with low dose temozolomide (TMZ) 3. High dose or metronomic TMZ alone 4. F/u with MRI scans every two months 5. If MRI documented progression: Avastin, repeat resection, radiosurgery, or clinical trials
  • 4.  
  • 5.  
  • 6.  
  • 7. Preop Axial T1 with Contrast
  • 8. Pre-resection motor stimulation with Ojemann Stimulator
  • 9. Post Resection: Motor Stimulation
  • 12.
  • 13.  
  • 14.
  • 15. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response Vascularized Periphery Perinecrotic Rim (Pseudopalisades ) Necrotic Area Thrombotic Vessel
  • 16. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response
  • 17.
  • 18.
  • 19. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response
  • 20.
  • 21. HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress
  • 22. GRP78 LEVELS IN GLIOBLASTOMA TISSUE SECTIONS
  • 23. TMZ increases GRP78 in glioblastoma cell lines. GRP78 Actin GRP78 Actin
  • 24. U87 glioblastoma cells transfected with different concentrations of GRP78 siRNA and GFP siRNA fused to rhodamine.
  • 25.  
  • 26.  
  • 27.  
  • 28. Glioma Cancer Stem Cells and ER Stress
  • 29. Neural Stem Cells and the Origin of Gliomas Nader Sanai, M.D., Arturo Alvarez-Buylla, Ph.D., and Mitchel S. Berger, M.D.
  • 30.
  • 31. x16 x48 Morphology of GCSC (D431)
  • 32. TMZ treatment with 15% BSA Treatment in 6well plate and transfer to 96well plate for MTT analysis 2009-10-01 TMZ (uM) % O.D. at 490nm TMZ (uM) % O.D. at 490nm Conclusion: TMZ is not cytotoxic to CSC. U251 w/ 15% BSA CSC w/ 15% BSA 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80 90 100 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80
  • 33. Is DMC Cytotoxic To Glioma Cancer Stem Cells (GCSC) ? U87 U251 CSC (single) CSC (sphere) DMC (uM) % O.D. at 490nm Condition: Medium +10% BSA, 48hr treatment 0 20 40 60 80 100 120 140 0 10 20 30 40 50 60 70 80 90 100
  • 34. Does DMC Enduces ER Stress in Glioma Cancer Stem Cells (CSC) ? 1 2 3 4 5 GRP78 Chop Actin 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM
  • 35. Does DMC Induce ER Stress in Glioma Cancer Stem Cells (CSC) ? 1 2 3 4 5 GRP78 Chop Actin Parp MGMT Conclusion: ER stress upregulated at DMC 60 uM in CSC. DMC at 60 uM reduces MGMT levels. 24hr treatment Cl. parp Parp 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM CSC-D431
  • 36.  
  • 37.  
  • 38.
  • 39.  
  • 40. May/2006 Dec/2006 Fibrillary Astrocytoma grade II ______________________________________________________________________________________________________________________________________ May/2008 Jun/2007
  • 41. JAN / 2007 MAY / 2008 Recurrente Anaplastic Oligodendroglioma ______________________________________________________________________________________________________________________________________ NOV / 2008
  • 42. Disease-free survival (6 months) ______________________________________________________________________________________________________________________________________ The median PFS rate was 48.2% for patients with GBM, 60% for patients with AA, and 66.6% for patients with AO.
  • 43.
  • 44.  
  • 45.  
  • 46. Development of an Implantable Pump for Convection Enhanced Delivery
  • 47.
  • 48.
  • 49.  
  • 50. www.pharmaco-kinesis.com Convection Enhanced Trials 1. Some success in Phase I/II trials 2. No clear success in Phase III trials (Neopharm, Transmid) 3. Question: Lack of success from delivery or from drug?
  • 51.
  • 52.
  • 53.  
  • 54.
  • 55. 9/19/2008 Property of Pharmaco Kinesis Corp.
  • 56.
  • 57. Fig. 8 www.pharmaco-kinesis.com Medication Storage and Delivery System Circulation pump Medication pump Medication Reservoirs Catheter Catheter Cross Section Fluid Circulation System
  • 58.  
  • 62.
  • 63. Cir. And Reservoir Pump ( Bartels ) Active Valve ( Bartels ) Flow Sensor ( Sensirion ) Pressure Sensor Temperature Sensor ( GE ) pH Sensor ( WPI ) Reservior ( Metal Bellows ) www.pharmaco-kinesis.com
  • 64. www.pharmaco-kinesis.com Wireless Radio High level goals High level tasks Internal states Growth signal Intracranial pressure Tissue condition Tissue metabolism Table of parameters Circulate Inject 1 Inject 2 Inject 3 Pump Pump-valve Pump-valve Pump-valve VEGF Spectrometer Pressure sensor pH sensor Oxygen sensor Solid Tumor Microcontroller Medication Tumor Fluid
  • 65.
  • 66. www.pharmaco-kinesis.com Avastin in 28-day pump Implantated IP CPT-11 D7 – D11 D14 – D118 D21 – D25 D28 – D32 1 st dose of Avastin 2nd dose of Avastin
  • 67.
  • 68.  
  • 69.
  • 70. U87 intra-cerebral glioma model for in vivo analysis of RCR vector-mediated suicide gene therapy Establishment of tumor 1 x 10 t.u. ACE-CD injected into tumor 4 Intraperitoneal injection of 5-FC H&E / IHC Survival analysis virus spread 2 x 10 U87 tumor cells injected into nude mice 5
  • 71.
  • 72.
  • 73.
  • 74.
  • 75.
  • 76.
  • 77.
  • 78.
  • 79.